Inicio9VC • ETR
add
ATAI Life Sciences NV
Cierre anterior
1,31 €
Intervalo diario
1,34 € - 1,34 €
Intervalo anual
0,93 € - 2,50 €
Cap. bursátil
305,69 M USD
Volumen medio
1,60 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
NASDAQ
Noticias sobre los mercados
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Ingresos | -5,00 mil | -127,78 % |
Gastos operativos | 29,34 M | -12,62 % |
Ingresos netos | -38,96 M | -112,98 % |
Margen de beneficio neto | 779,16 mil | 866,72 % |
Beneficios por acción | -0,24 | -100,00 % |
EBITDA | -29,12 M | 12,97 % |
Tipo impositivo efectivo | 1,81 % | — |
Balance general
Activos totales
Responsabilidades totales
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 62,33 M | -65,23 % |
Activos totales | 159,39 M | -45,69 % |
Responsabilidades totales | 42,83 M | -12,87 % |
Patrimonio total | 116,55 M | — |
Acciones en circulación | 198,31 M | — |
Precio-valor contable | 1,89 | — |
Rentabilidad económica | -41,11 % | — |
Retorno sobre capital | -46,44 % | — |
Flujo de caja
Variación neta del flujo de caja
| (USD) | dic 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -38,96 M | -112,98 % |
Efectivo de operaciones | -24,30 M | -10,62 % |
Efectivo de inversión | 6,56 M | 897,08 % |
Efectivo de financiación | 154,00 mil | 101,82 % |
Variación neta del flujo de caja | -17,46 M | 44,50 % |
Flujo de caja libre | -1,72 M | 86,74 % |
Información sobre la empresa
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine.
In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff.
Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Director ejecutivo
Fundación
2018
Sitio web
Empleados
54
